# CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

> **NCT04186520** · PHASE1,PHASE2 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 100 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma (NHL)
- Mantle Cell Lymphoma (MCL)
- Chronic Lymphocytic Leukemia (CLL)
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Central Nervous System Lymphoma

## Interventions

- **BIOLOGICAL:** 8/12-Day Production of Car-T Cells
- **BIOLOGICAL:** 8/12-Day Production of Cryopreserved Car-T Cells
- **BIOLOGICAL:** 12-Day Production of Car-T Cells

## Key facts

- **NCT ID:** NCT04186520
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-18
- **Primary completion:** 2027-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04186520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04186520, "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04186520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*